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a  b  s  t  r  a  c  t
Phytoestrogens  are  plant-derived  estrogen-like  compounds  that  are  increasingly  used  for
their suggested  health  promoting  properties,  even  by  healthy,  young  women.  However,
scientiﬁc  concerns  exist  regarding  potential  adverse  effects  on  female  reproduction.  In this
study,  naringenin  (NAR),  8-prenylnaringenin  (8-PN),  genistein  (GEN),  coumestrol  (COU),
quercetin  (QUE)  and  resveratrol  (RSV)  up-regulated  steroidogenic  acute  regulatory  protein
(StaR) mRNA  levels  in  KGN  human  granulosa-like  tumor  cells.  Most  of  the  phytoestrogens
tested  also  increased  CYP19A1  (aromatase)  mRNA  levels  via activation  of  ovary-speciﬁc  I.3
and II  promoters.  Yet,  only NAR  (3 and  10 M),  COU (10  and  30 M)  and  QUE  (10 M)
also  statistically  signiﬁcantly  induced  aromatase  activity  in KGN  cells after  24  h. 8-PN,
aromatase  inhibitor  letrozole  and  estrogen  receptor  antagonist  ICI  182,780  concentration-
dependently  inhibited  aromatase  activity  with  IC50 values  of 8 nM,  10 nM  and 72  nM,
respectively.  Co-exposure  with  ICI 182,780  (0.1 M) statistically  signiﬁcantly  attenuated
the  induction  of  aromatase  activity  by QUE  and  COU,  but not  NAR.  Cell  cycle  status  and pro-
liferation  of KGN  cells  were  not  affected  by  any of the  phytoestrogens  tested.  Nonetheless,
the  migration  of KGN  cells  was  signiﬁcantly  reduced  with  approximately  30%  by COU,  RSV
and QUE  and  46% by  GEN  at 10 M, but not  NAR  and  8-PN.  Our  results  indicate  that  phy-
toestrogens  can affect  various  pathways  in  granulosa-like  cells  in vitro  at concentrations
that  can  be found  in  plasma  upon  supplement  intake.  This  implies  that  phytoestrogens  may
interfere with  ovarian  function  and caution  is  in  place  regarding  the  use  of  supplements
with  high  contents  of phytoestrogens.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe CC  B∗ Corresponding author at: Endocrine Toxicology Research Group,
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1. Introduction
Phytoestrogens are naturally occurring plant com-
pounds that are omnipresent in our daily diet. Over the
past  years, phytoestrogens have attracted much attention
due  to their estrogenic or anti-estrogenic properties and
their  potential use as alternatives for hormone replace-
ment therapy in postmenopausal women. In addition,
supplements that contain high levels of phytoestrogens are
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ommercially available for breast enhancement and relieve
f  menstrual complaints. Phytoestrogens are diverse plant-
erived  group of compounds and they consist of several
roups of different chemical classes classiﬁed according
o  their chemical structure including ﬂavanoids, coumes-
ans  and lignans. Most ﬂavanoids are present in plants in
he  conjugated glycoside forms and can be readily hydrol-
sed  by gastrointestinal bacteria to biologically active
glycones [1]. There is considerable interest in whether
uman exposure to phytoestrogens has any health risks
r  beneﬁts due to the increase of nutritional and phar-
aceutical use of dietary phytoestrogenic compounds
2,3]. Epidemiologic evidence mainly based on Asian
opulation studies, supports a protective effect of high
hytoestrogen diets to reduce the incidence of certain
ormone-responsive cancers, such as breast and prostate
ancer. Contrary, there have been concerns that phytoes-
rogens, through their estrogenic properties, may  increase
he  risk of recurrence or stimulate the growth of exist-
ng  tumors. In addition, numerous in vivo and in vitro
tudies have demonstrated altered ovarian function and
hanges  in the developing female reproductive system fol-
owing  exposure to phytoestrogens in laboratory animal
tudies [4–6]. Phytoestrogens were able to affect female
eproductive function by modulating the female cycles
hat  in turn resulted in infertility in animals [7,8] and
umans [9,10]. In humans, the prevalence of precocious
uberty was signiﬁcantly higher in Korean girls with high
erum  isoﬂavone levels [11]. Despite the numerous stud-
es,  the molecular mechanisms underlying the adverse
ffects of phytoestrogens on ovarian function still remain
lusive.
It  is well known that phytoestrogens may disrupt
ndocrine-dependent processes by acting as estrogen
eceptor (ER) agonists or antagonist due to their bi-
henolic structure required for ligand–receptor associa-
ion. Phytoestrogens can bind weakly to ERs, typically
ith afﬁnities that are 1000 times less than that of 17-
stradiol (E2) [12]. ER receptor is a classical steroid
eceptor predominantly expressed in granulosa cells. In
ontrast,  ER protein is expressed at low levels in granulosa
ells [13]. Several phytoestrogens are selective estrogen
eceptor modulators that have greater afﬁnity for ER
han  ER [14]. In addition to classical estrogen recep-
ors, phytoestrogens were shown to be ligands for the
on-classical estrogen receptor G-protein coupled pro-
ein  receptor 1 GPER1 [15]. Moreover, it has become clear
hat  phytoestrogens can exert endocrine disrupting prop-
rties  by inhibiting key steroidogenic enzymes. During
uberty, E2 that is synthesized and secreted by granulosa
ells in the ovaries, modulates the structure and func-
ion  of female estrogen-sensitive tissues and contributes to
aintaining  a proper menstrual cycle pattern and female
exual  behavior. Ovarian steroidogenesis is initiated by the
elivery  of cholesterol from cytosol into the mitochon-
ria by the steroidogenic acute regulatory protein (StAR)
16,17]. The ﬁnal step in estrogen synthesis is catalyzed
y aromatase (CYP19A1), which converts androgens into
strogens. Human CYP19A1 comprises of ten exons includ-
ng  exons II–X that encode the aromatase protein and
′-untranslated region of the mRNA. Alternative ﬁrst exonsorts 1 (2014) 360–372 361
encode  unique 5′-untranslated regions of the aromatase
mRNA transcripts in different estrogen-producing tissues
[18,19]. Aromatase transcripts in gonads, brain, adipose
and  placenta contain different ﬁrst exons (II, If, I.4/I.3
and I.1, respectively) and the expression of CYP19A1 in
each  of these organs is controlled by alternatively spliced
tissue-speciﬁc promoters regulated by distinct signaling
pathways in a hormone-speciﬁc manner [19–23]. In ovar-
ian  granulosa cells, aromatase expression is FSH-driven and
is  regulated via the ovary-speciﬁc PII promoter [21]. Many
studies  with various models have shown the inhibitory
effects of phytoestrogens on aromatase activity [24–29],
while other phytoestrogens induce aromatase activity
[30,31].
The  aim of our work was  to study the effects of several
potent phytoestrogens that are frequently used in dietary
supplements as possible modulators of ovarian function
and  cellular behavior in vitro. It should be noted that many
phytoestrogens are omnipresent in our daily diet, albeit at
much  lower concentrations than can be found in dietary
supplements. The data from these studies were used to
assess  the potential risk for ovarian dysfunction in humans
upon  high intake levels of phytoestrogens including narin-
genin  (NAR), 8-prenylnaringenin (8-PN), genistein (GEN),
coumestrol (COU), quercetin (QUE) and resveratrol (RSV)
(for  chemical structures see supplementary data Fig. S1).
These  phytoestrogens were selected for their previously
reported induction (GEN and QUE) [30,31] or inhibition
(NAR and 8-PN) [29–31] and/or their reported effects on
ovarian  tumor cell behavior (RSV, GEN, QUE, COU) [32–34].
In  our study, we  used the KGN granulosa-like tumor cell
line  of human origin. KGN cells were previously shown
to  maintain many of the physiological features of normal
human granulosa cells, including steroidogenesis [35] and
secretion  of estrogens [36,37]. We show here that KGN
cells  display the ovarian-speciﬁc PII/I.3-driven aromatase
expression, similarly to normal granulosa cells surrounding
the  preovulatory follicle. KGN cells have also been reported
to  express both ERs [38]. Moreover, several studies have
demonstrated that KGN cells respond similarly to primary
human granulosa cells upon stimulation with, e.g. FSH
[39–41]. Therefore, this cell line is an excellent and appli-
cable in vitro model to study effects on human granulosa
cell functioning. Here, the action of the selected phytoes-
trogens on ovarian steroidogenic enzymes such as StAR and
CYP19A1  and its promoter-speciﬁc expression was  inves-
tigated.  Phytoestrogens have also been shown to affect a
wide  array of intracellular signaling mechanisms that are
important for regulating cell cycle progression. Therefore,
we  investigated to which extent phytoestrogens inﬂuence
the  metastatic properties of KGN cells by performing a
wound  healing assay. Finally, expression of several impor-
tant  genes involved in cell progression and/or death, were
studied.  We chose to study gene expression of VEGF, a crit-
ical  inducer of tumor angiogenesis and SIRT1, regulator of
cellular  lifespan and tumor promoter in mammary epithe-
lial  cells [32,42]. Moreover, gene expression of MMP9, a
prerequisite for enhanced cell migration, and CADHERIN
E,  adhesion-activated signaling receptor, were evaluated.
The  data from these in vitro studies were compared with
reported human plasma levels to assess the potential risk
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for ovarian dysfunction in humans upon high intake levels
of  phytoestrogens.
Supplementary Fig. S1 related to this arti-
cle can be found, in the online version, at
doi:10.1016/j.toxrep.2014.06.006.
2. Material and methods
2.1.  Cell culture
The  KGN granulosa-like tumor cells (kindly provided
by Riken Biosource Center, Tsukuba, Japan) were cul-
tured  in supplemented with 10% FBS (Invitrogen-Gibco)
phenol red-free DMEM/F12 (Invitrogen-Gibco), 100 U/ml
penicillin, 100 g/ml streptomycin (Invitrogen-Gibco) in
an  atmosphere of 5% CO2/95% air at 37 ◦C. KGN cells were
subcultured 1:2 once a week. For all experimental con-
ditions, media were replaced with 5% steroid free Serum
dextran/charcoal (Hyclone; Invitrogen-Gibco), 100 U/ml
penicillin, 100 g/ml streptomycin (Invitrogen-Gibco) and
KGN  cells were grown for next 4 days before treatments.
2.2. Chemicals and reagents
Estradiol  (E2), NAR, 8-PN and dexamethasone (DEX)
were dissolved in ethanol. GEN, COU, QUE, RSV, ICI
182,780 and Prostaglandin E2 (PGE2) were dissolved
in dimethyl sulfoxide (DMSO). 5-Bromo-2-deoxyuridine
(BrdU) was dissolved in Phosphate buffered saline (PBS). All
compounds  were purchased from Sigma–Aldrich Co. (Zwi-
jndrecht,  The Netherlands), unless indicated otherwise.
BrdU was purchased from Euro-diagnostics bv, Apeldoorn,
the  Netherlands. The concentration of each solvent was set
as  0.1% of the culture medium.
2.3. Cytotoxicity assay
Cell  viability was determined according to Deni-
zot and Lang [43] by measuring the capacity of
KGN cells to reduce MTT  (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) to formazan by the
mitochondrial enzyme succinate dehydrogenase. Brieﬂy,
KGN  cells (0.1 × 106) were plated in 24 well plates
in assay medium and then incubated for 1.5 h with
MTT  at 37 ◦C. After that time, the formed blue colored
formazan was extracted by adding 1 mL  of isopropanol
at room temperature (RT). Absorbance was measured
spectrophotometrically at an absorbance wavelength of
595  nm (POLARstar Galaxy, BMG  Labtech GmbH, Orten-
berg,  Germany).
2.4.  Quantitative real time polymerase chain reaction
(RT-PCR)
Gene expression studies were performed in KGN cells.
Brieﬂy, KGN cells (2.5 × 105 cells) were seeded in 12-well
plates in assay phenol red-free DMEM/F12 medium. Cells
were  exposed to NAR and 8-PN at 3 M;  GEN, COU, QUE
and  RSV at 10 M for 24 h. PGE2 (0.1 M),  a potent sti-
mulator of steroidogenic genes such as StAR and CYP19A1
of  ovarian-related aromatase [44] was used as a positiveorts 1 (2014) 360–372
control for aromatase induction. Total RNA was har-
vested from the KGN cells by phenol–chloroform extraction
using RNA Instapure (Eurogenetic, Liege, Belgium). Purity
and  concentration of the RNA samples were determined
spectrophotometrically at an absorbance wavelength of
260/280  nm and 230/260 nm.  Complementary DNA (cDNA)
was  synthesized using iScript cDNA Synthesis Kit, accord-
ing  to the manufacturer’s instructions (Biorad, Veenendaal,
the  Netherlands). Obtained cDNA was diluted 10 times and
stored  at −20 ◦C until further analysis. The qRT-PCR was
performed using CFX Manager (Biorad, Veenendaal, the
Netherlands). PCR reaction was  initiated by heating at 95 ◦C
for  3 min, then followed by 40 cycles with denaturation at
95 ◦C for 15 s, annealing/extension at 60 ◦C for 45 s. After
each  run a melt curve was  performed to ensure that primer-
dimers and other non-speciﬁc products were omitted. A
negative  control sample (non-RT) was  included in each
run.  The primers for ˇ-Actin, I.3, PII, I.4, Vascular Endothe-
lial  Growth Factor (VEGF) have been described previously
[45,46]. All primer pairs used in the qRT-PCRs are listed
in  Table 1. The primers were designed using Primer-BLAST
of National Center for Biotechnology Information (NCBI)
and  then checked with BLAST (nucleotide nonredundant
database) to conﬁrm speciﬁcity. The ˇ-Actin gene expres-
sion  was  not affected by tested phytoestrogens, thus it was
used  as housekeeping gene in the present study.
2.5. Aromatase (CYP19A1) activity
CYP19A1 (aromatase) activity was determined in KGN
cells  after a 24-h exposure using the tritiated water-release
method of Lephart and Simpson [47] with minor modiﬁca-
tion  by Sanderson et al. [48]. Brieﬂy, KGN cells (0.1 × 106)
were  seeded onto 24 well plates in assay medium. CYP19A1
activity was  measured as the amount of tritiated water
formed after the conversion of the CYP19A1 enzyme’s sub-
strate  [1−3H)-androstenedione. PGE2 (0.1 M),  was used
as  a positive control for aromatase catalytic activation.
2.6. Protein extraction and western blot analysis
KGN cells (6 × 106) were washed once with warm PBS,
then trypsinized. Cells were centrifuged and 250 L of
PBS  was added to each cell pellet. Cells were lysed using
adopted freeze-thaw lysis method using liquid-Nitrogen
and 37 ◦C water bath by alternatively incubating at least
3  times The total protein concentration of lysates was
quantiﬁed using he Lowry assay [49]. 30 g of cell pro-
tein and protein standards were fractionated by SDS-PAGE
(10%), electrophoretically transferred onto polyvinylidene
ﬂuoride (pvdf) membrane and probed for 1 h at RT
with a primary rabbit monoclonal antibody recommended
for detection of human CYP19A1, dilution factor 1:1000
(Abcam). After washing, the membranes were incubated
for  another 1 h at RT with a secondary polyclonal goat
anti-rabbit antibody conjugated to the enzyme horseradish
peroxidase (HRP), dilution factor 1:1000 (Abcam). Protein
bands  were visualized by chemiluminescence using Bio-
Rad  ClarityTM western ECL substrate kit. Precision Plus
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Table 1
Primers used for qRT-PCR.
Gene name Forward primer Reverse primer PCR product [bp]
ˇ-Actina AAACTACCTTCAACTCCATC ATGATCTTGATCTTCATTGT 163
I.3  GCTGCAATTCAAGCCAAAAG GCACGATGCTGGTGATGTTATA 187
PI  TCTGTCCCTTTGATTTCCACAG GCACGATGCTGGTGATGTTATA 112
I.4  GGCTCCAAGTAGAACGTGACCAACTG CAGCCCAAGTTTGCTGCCGAA 475
CYP19A1 TTGGGCTGCAGTGCATCGGT CCGGGGCCTGACAGAGCTTTCATA 109
StAR TGGCAGTACATGTGCACAAAGCAG CTGCTTGTTCTGTGGTGTTGCTGT 94
SIRT1 TCTGGCATGTCCCACTATCA GCAGATTAGTAGGCGGCTTG 152




































(MMP9  GGCTCCTGGCACACGCCTTT 
VGEF ATCACGAAGTGGTGAAGTTC 
a Gene used as reference normalizer gene.
roteinTM Standards were used at the 10–250 kDa range
s  the markers (Bio-Rad Laboratories, Inc.).
.7. Wound healing assay
The  wound-healing assay was described previously [50]
nd  was used to determine whether KGN cell motility
ould be affected by diverse phytoestrogens. KGN cells
0.7  × 106) were cultured in 12-well cell plates until conﬂu-
ncy. Wounds were made by scratching the cellular layer
ith  a 100 L pipette tip in the middle of the well. After
ashing away the cell debris, assay medium with tested
hytoestrogens was added to the culture. Zero hour pic-
ures  (0 h-control) were taken for each wound with an
lympus U-CMAD3 camera. Cells were incubated for 8 and
4  h and then another picture for each wound was taken.
he  wound area was measured with an Image J 1.47c soft-
are  (National Institutes of Health, USA).
.8. BRdU staining
KGN  cells (0.7 × 106) were cultured in 12-well cell
lates until conﬂuent. BrdU (10 M)  was added to cul-
ure  medium for 1 h. When added to culture medium, BrdU
10  M)  is incorporated into the DNA of cells that are in the
-phase  of the cell cycle [51]. Then, KGN cells were ﬁxed in
ce-cold  methanol for 20 min  at 37 ◦C. Immunocytochem-
cal detection of BrDU labled DNA was performed using
ndiluted anti-BrDU and peroxidase-conjugated Rabbit-
nti-mouse Ig (RAM-PO, dilution factor: 1:40) for 90 and
0  min, respectively.
.9. Cell cycle analysis
Cell  cycle analysis was determined according to proto-
ol  described by Sangjun et al. [52]. KGN cells (0.25 × 106)
ere  plated onto 12-well plates and further cultured with
hytoestrogens for 24 h. Cells were then trypsinized, ﬁxed
nd  permeabilized with 70% ethanol for at least 30 min  at
◦C. KGN cells were then labeled with propidium iodide
or  10 min  at room temperature (RT). The samples were
sed  for ﬂow cytometry (FACS, Calibur, Becton Dickinson)
o  determine the cell cycle distribution of the KGN cells. The
ow  cytometry data was analyzed using Flowjoj software
Tree  Star, Inc., USA).TGGAACCACGACGCCCTTGC 101
TGCTGTAGGAAGCTCATCTC 265
2.10.  Data analysis and statistics
All experiments were performed at least three times and
within  each independent experiment each concentration
was tested in duplicate (aromatase activity) or triplicate.
The  results are displayed as the mean of replicates of each
experiment with standard deviation (SD). Statistical anal-
ysis  of difference of the means between vehicle-treated
control (either Ethanol (0.1%) or DMSO (0.1%) or com-
bination of both)-treated cells was  determined using a
two-tailed unpaired Students’ t-test or a one-way ANOVA
and  post hoc Dunnett’s test. Calculations are performed
using GraphPad Prism 6.01 (GraphPad Software Inc., San
Diego,  USA). Differences were considered statistically sig-
niﬁcant  with P < 0.05.
3. Results
3.1. MTT cytotoxicity assay
None  of the tested compounds was  cytotoxic at the
highest concentration tested, except for GEN (30 M)  and
COU  (30 M)  (supplementary data Fig. S2B). At the highest
concentrations tested, GEN and COU reduced cell viability
by  20 and 15%, respectively when compared to vehicle-
treated control cells. In the subsequent experiments with
KGN  cells, non-cytotoxic concentrations of phytoestrogens
were used.
Supplementary Fig. S2 related to this article can
be found, in the online version, at doi:10.1016/
j.toxrep.2014.06.006.
3.2. Modulation of aromatase in KGN cells
3.2.1. Aromatase (CYP19A1) gene expression
Aromatase (CYP19A1) expressed in granulosa cells sur-
rounding the developing oocyte in the ovary, is responsible
for  conversion of androgens into estrogens. CYP19A1 mRNA
levels  in KGN cells statistically signiﬁcantly increased
by 2.3, 1.9 and 3.2-fold after a 24-h exposure to 8-PN
(3  M),  GEN (10 M)  and QUE (10 M).  No changes in
CYP19A1 mRNA levels were seen in NAR (3 M),  COU
(10 M)  and RSV (10 M)  treated-KGN cells (Fig. 1A). A
24-h  exposure to PGE2 (0.1 M)  increased CYP19A1 mRNA
by  approximately 7-fold compared with vehicle-treated
control cells (Fig. 1A). Using qRT-PCR, we  showed that
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Fig. 1. Gene expression in KGN cells after a 24-h exposure to various
phytoestrogens. (A) CYP19A1 mRNA levels. Signiﬁcant up-regulation of
CYP19A1 mRNA after exposure to 8-PN (3 M),  GEN (10 M)  and QUE
(10 M).  PGE2 (0.1 M)  was used as a positive control. (B) Promoter P1.3-
and PII-speciﬁc expression of CYP19A1 mRNA. Signiﬁcant up-regulation
of PI.3 and PII – driven CYP19A1 mRNA after exposure to 8-PN (3 M),
GEN (10 M)  and QUE (10 M).  PGE2 (0.1 M) was  used as a positive
control. Data are expressed as fold-change compared with expression
in vehicle-control treated cells. Bars represent mean + SD of three inde-
pendent experiments that were performed in triplicate (N = 3). * and #
are  up-regulated by diverse phytoestrogenssigniﬁcantly from relevant solvent vehicle control Ethanol (0.1%) or DMSO
(0.1%)-treated cells, respectively. P < 0.05.
aromatase expression in KGN cells was promoter II (PII)
and  I.3-driven, as expected based on its ovarian origin.
Expression of both PII- and I.3-driven CYP19A1 was sta-
tistically signiﬁcantly up-regulated by PGE2 (0.1 M)  after
24  h and increased 3.5- and 4-fold for I.3 and PII, respec-
tively (Fig. 1B). Neither promoter I.4 nor I.1-driven CYP19A1
expression was detected in KGN cells (data not shown).
Also, DEX (0.1 M),  a potent inducer of promoter I.4-
driven transcription of CYP19A1 did not induce aromatase
gene expression and activity (data not shown). Based on
these  data, we tested the effects of phytoestrogens only
on  PII/1.3-driven CYP19A1 gene expression. Among the
phytoestrogens tested, QUE (10 M)  was the most potent
activator of PI.3 and PII-driven CYP19A1 (3.5- and 3-fold
induction, respectively). Also 8-PN and GEN statistically
signiﬁcantly up-regulated PII/PI.3-driven CYP19A1 expres-
sion.  8-PN (3 M)  signiﬁcantly up-regulated CYP19A1 via
promoters 1.3 and II by 1.8- and 2-fold, respectively. GEN
(10  M)  had more potent effects toward activation of PI.3
promoter than PII, with a statistically signiﬁcantly increaseorts 1 (2014) 360–372
of  I.3 promoter-driven CYP19A1 mRNA to about 2-fold com-
pared  with vehicle-treated control cells. Neither NAR nor
COU  and RSV affected promoter-speciﬁc mRNA expression
of  CYP19A1. Taken together, the results demonstrated sti-
mulatory  effects of diverse phytoestrogens on promoter I.3
and  II-driven mRNA of CYP19A1 in KGN cells.
3.2.2. Aromatase CYP19A1 enzyme activity and
expression
The known inducer of ovarian-type aromatase PGE2
(0.1 M)  statistically signiﬁcantly induced aromatase
activity up to 315% compared with vehicle-treated control
cells  (data not shown). In contrast, the known spe-
ciﬁc CYP19A1 enzyme inhibitor letrozole concentration-
dependently inhibited CYP19A1 activity in KGN cells (IC50
value of 10 nM;  Fig. 2A). Of all tested phytoestrogens,
only 8-PN inhibited aromatase activity (IC50 value of
8  nM;  Fig. 2B). COU and NAR concentration-dependently
increased aromatase activity to approximately 155% at
non-cytotoxic concentrations of 10 M when compared
to vehicle-treated control cells (Fig. 2B and C). Appar-
ent EC50 values for induction of aromatase activity were
10  and 1.3 M for COU and NAR, respectively. QUE was
the  most potent CYP19A1 activator with an EC50 value
of  4.7 M and a maximum induction of 210% at 10 M.
Notably, there was a sharp and signiﬁcant decline in aro-
matase  activity after QUE exposure at 30 M (Fig. 2C).
This  decline was not due to cytotoxicity (supplementary
data Fig. S2B). The phytoestrogens GEN and RSV did not
affect  CYP19A1 activity at any of the tested concentrations
(Fig. 2C). Because of the differential effects of phytoestro-
gens on CYP19A1 gene expression and aromatase activity,
CYP19A1 protein expression was determined by western
blot.  A slight increase in protein level of CYP19A1 was
observed by PGE2 (0.1 M)  and COU (10 M)-treated KGN
cells  after 24 h. However, no changes at CYP19A1 protein
level  were observed after 24-h exposure to 8-PN (3 M),
GEN  (10 M)  and QUE (10 M)  (supplementary data Fig.
S3).
Supplementary Fig. S3 related to this article can
be found, in the online version, at doi:10.1016/
j.toxrep.2014.06.006.
Phytoestrogens are suggested to exert their effects
mainly via estrogen receptors. Therefore, we studied the
potential involvement of estrogen receptor  (ER) in the
activation of aromatase by non-cytotoxic concentrations
of NAR, COU and QUE. Exposure to E2 (0.001–0.1 M)
did  not have a statistically signiﬁcant effect on CYP19A1
activity (data not shown). However, the known pure
ER antagonist ICI 182,780 concentration-dependently
reduced aromatase activity (IC50 value of 72 nM;  Fig. 2A).
Moreover, co-exposure with ICI 182,780 (0.1 M)  and COU
(10  M)  or QUE (10 M),  but not NAR (3 M),  statistically
signiﬁcantly decreased aromatase activity in KGN cells
when  compared to COU or QUE exposed cells alone (Fig. 3).
3.3.  Steroidogenic acute regulatory protein mRNA levelsPhytoestrogen-mediated effects on StAR mRNA expres-
sion  were determined in KGN cells. Results showed
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Fig. 2. Aromatase activity in KGN cells. (A) Concentration-dependent
inhibition  curve of Letrozole and ICI 182,780. (B) 24 h-exposure to dif-
ferent concentrations of NAR and 8-PN. (C) Effects of COU, GEN, RSV and
QUE at diverse concentrations on aromatase activity. Data are expressed
as % of aromatase activity compared with 100% of aromatase activity in












Fig. 3. Aromatase activity in KGN cells exposed to ICI (0.1 M), NAR
(3 M),  COU (10 M) and QUE (10 M).  Striped bars present a co-exposure
of ICI (0.1 M) with tested phytoestrogens. Data are expressed as % of
aromatase activity compared with 100% of aromatase activity in vehicle-
control treated cells. The experiments were performed in duplicates and
repeated three or four times (N = 3; N = 4). * or # signiﬁcantly different
from relevant solvent vehicle control Ethanol (0.1%) and/or DMSO (0.1%)-
treated cells, respectively. ## signiﬁcantly different from COU (10 M) or
QUE (10 M)-exposed cells. P < 0.05.
Fig. 4. StAR mRNA expression in KGN cells after a 24-h exposure to
diverse phytoestrogens. Data are expressed as fold-change compared with
expression in vehicle-control treated cells. Bars represent mean + SD ofates and repeated three or four times (N = 3; N = 4). * and/or # signiﬁcantly
ifferent from relevant solvent vehicle control Ethanol (0.1%) or DMSO
0.1%)-treated cells, respectively. P < 0.05.
hat StAR mRNA levels were statistically signiﬁcantly up-
egulated after a 24 h-exposure to 8-PN (2.3-fold), 10 M
OU  (1.9 fold), 10 M QUE (2.2-fold), and 10 M RSV (2-
old)  (Fig. 4). Also 0.1 M PGE2 up-regulated StAR mRNA
y  approximately 2.5-fold (Fig. 4).
.4. Phytoestrogens do not impair cell cycle but affect cell
igration
A  wound-healing assay was performed to determine
he effect of phytoestrogens on KGN cell migration. Tothree  independent experiments that were performed in triplicate (N = 3).
*  and# signiﬁcantly different from relevant solvent vehicle control Ethanol
(0.1%) or DMSO (0.1%)-treated cells, respectively. P < 0.05.
determine the migratory properties of KGN cells, wound
healing was  assessed at 0, 8 and 24 h after inﬂicting
the wound. In vehicle-treated KGN cells, the wound area
was  89% ± 6 and 40% ± 2 after 8 and 24 h, respectively,
compared with the initial wound area. Based on this, a 24 h-
time  point was  chosen to evaluate possible inhibition or
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Fig. 5. Effects of phytoestrogens on KGN cell migration. (A) The examples of pictures of wound-healing assay at time 0 h and after 24 h-exposure of KGN
tation o
dent ex
.1%)-trecells  to different phytoestrogens. Magniﬁcation 4×. (B) Graphical presen
vehicle-control  treated cells. Bars represent mean + SD of three indepen
different from relevant solvent vehicle control Ethanol (0.1%) or DMSO (0
induction of phytoestrogens on KGN cell migration. The
phytoestrogens tested decreased migration of KGN cells
after  a 24 h-exposure (Fig. 5A and B). GEN (10 M)  exerted
the  most pronounced effect on cell mobility and statisti-
cally  signiﬁcantly inhibited migration of KGN cells to 46%
compared with vehicle-treated control cells. The phytoes-
trogens COU (10 M),  QUE (10 M)  and RSV (10 M),  but
not  NAR (3 M)  and 8-PN (3 M),  decreased cell migra-
tion to about 25–30% compared to vehicle-treated control
cells  after 24 h (Fig. 5A and B). To ensure that the observed
changes on migration were not due to the proliferative
effects of phytoestrogens, routine BrdU labeling of prolif-
erating cells was employed and KGN cells were analyzed
after a 24-h treatment with the tested phytoestrogens. No
changes  in cell proliferation of KGN cells were detected
upon exposure to the tested phytoestrogens (data not
shown). Moreover, cell cycle analysis by ﬂow cytometry did
not  reveal any signiﬁcant changes in distribution in phase S,
G1  and G2 of KGN cells (supplementary data Fig. S4). Thesef wound-healing assay. Data are shown as fold-change compared with
periments that were performed in triplicate (N = 3). * or # signiﬁcantly
ated cells, respectively. P < 0.05.
results  clearly indicate that phytoestrogens did not affect
KGN  cell proliferation nor cell cycle distribution after 24 h.
Supplementary Fig. S4 related to this article can
be found, in the online version, at doi:10.1016/
j.toxrep.2014.06.006.
3.5. Marginal effects of phytoestrogens on mRNA levels of
genes  implicated with tumor growth and progression
To investigate potential molecular mechanisms behind
the  inhibition of migration of KGN cells, expression of sev-
eral  genes that are important in tumor progression was
determined. Only GEN (10 M)  statistically signiﬁcantly
up-regulated VEGF gene expression up to 1.5-fold com-
pared  with vehicle-treated control cells (supplementary
data Fig. S5A). 8-PN (3 M)  caused a statistically signiﬁcant
1.9-fold induction of SIRT1 gene expression (supplemen-
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tatistically signiﬁcantly affected MMP9  and CADHERIN E
RNA  levels (supplementary data Fig. S5B).
Supplementary Fig. S5 related to this article can
e found, in the online version, at doi:10.1016/
.toxrep.2014.06.006.
. Discussion
Phytoestrogens are plant-derived estrogen-like com-
ounds that are increasingly used for their suggested
ealth promoting properties, even by healthy, young
omen. However, scientiﬁc concerns exist regarding
otential adverse effects on female reproduction. Here,
e  show that some phytoestrogens can modulate
varian-speciﬁc aromatase expression and activity. Also,
ome  phytoestrogens affected migration of human KGN
ranulosa-like tumor cells.
This study is the ﬁrst to describe the presence and acti-
ation of the ovary-speciﬁc promoters II and I.3 in KGN
ells.  Within the ovary, aromatase expression is mediated
rimarily by gonadotropin receptors and the cyclic-AMP
ependent signaling pathway, which ﬁnally contributes to
n  interaction and activation of the cyclic AMP  response
lement binding protein (CREB) and steroidogenic factor
 (SF-1) with proximal promoter II and I.3 [53]. Interest-
ngly, it is well-known that the activation of promoters
.3 and II is a critical step for abnormal expression of
romatase levels and local estrogen biosynthesis in tumor-
earing  breast tissues [54]. Both promoters I.3 and II
re  located closely to each other (215 base pair dis-
ance length) and are uniformly up-regulated by PGE2
ia  a cAMP-PKA-dependent pathway [55]. It has been
ell  documented that in ovarian granulosa cells, CYP19A1
xpression is regulated primarily by promoter II [56,57].
e  showed that PGE2 (0.1 M)  signiﬁcantly up-regulated
RNA of both I.3 and II promoter-driven CYP19A1 and
ncreased aromatase activity up to 350% when compared
o  vehicle-treated control cells. Similarly to PGE2, QUE
10  M)  induced CYP19A1 expression via I.3 and II promo-
ers  in KGN cells and increased CYP19A1 activity up to 3
old  after a 24-h exposure. Similarly, QUE (10 and 30 M)
as  found to increase I.3 and II-speciﬁc aromatase trans-
ripts  to approximately 2.6- and 2-fold after 24 h exposure
n  human adrenal H295R cells [31]. However, in a pri-
ary  culture of human granulosa-luteal cells, QUE (10 M)
educed  CYP19A1 mRNA expression in a concentration-
ependent manner after an exposure period of 48 h [28].
he  same inhibitory effect of QUE upon aromatase activ-
ty  was observed in human placental microsomes [58].
nterestingly, in the present study, QUE appeared to exert
ual  effects on aromatase at non-cytotoxic concentrations,
here it stimulated aromatase activity up to 10 M and
nhibited its activity at 30 M.  This type of non-monotonic
romatase activity curve after exposure to QUE was also
bserved in human adrenal H295R cells [31]. In the study of
anderson  et al., the concentration of 30 M QUE increased
romatase activity to approximately 4-fold, where after
here  was a sharp decline in aromatase activity. However,
n  that study the decline in aromatase activity was  con-
omitant with an increase in cytotoxicity of QUE at 100 M
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production in primary cultures of human granulosa-luteal
cells [59]. Also differential effects of GEN on aromatase reg-
ulation  have been reported in gonadal cells. In our study,
aromatase activity and protein expression remained unal-
tered  in the presence of 10 M of GEN. Edmunds et al. and
Myllymaki et al. reported an increase of aromatase activity
in  human endometrial stromal cells and immature rat ovar-
ian  follicles after exposure to GEN [60,61]. In contrast, Rice
et  al. demonstrated that the CYP19A1 mRNA transcripts
and aromatase activity were reduced in human granulosa-
luteal cells after exposure to 10 and 50 M GEN [28]. In
the  present study, GEN (10 M)  signiﬁcantly up-regulated
CYP19A1 expression, which was  mostly PI.3-driven. Ye et al.
showed  a concentration-dependent induction of mRNA
expression of both promoters I.3 and II CYP19A1 transcripts
in  human HepG2 cells after exposure to 10 M GEN [62].
In  human adrenal H295R cells, PII and to a lesser extent the
I.3  promoter-driven CYP19A1 transcripts were increased by
GEN  at 10 M [31].
Some dietary ﬂavanones have previously been shown to
possess  strong aromatase-inhibitory effects [29], nonethe-
less,  their effects on the transcriptional regulation of
CYP19A1 and its promoter regions at mRNA level, remain
unknown. In our study, 8-PN (3 M)  but not NAR
(3 M)  increased mRNA levels of both PII and I.3-driven
CYP19A1 in KGN cells up to 1.8- and 2-fold, respec-
tively. Consistently, 8-PN up-regulated CYP19A1 mRNA
transcripts, although CYP19A1 activity was  concentration-
dependently inhibited (IC50 value of 8 nM). Yet, no change
at  protein level of CYP19A1 was  detected after a 24-h expo-
sure  to 8-PN. This implies that 8-PN acts as a catalytic
inhibitor of aromatase activity and that the 8-prenyl group
is  involved in inhibition of aromatase activity. It is interest-
ing  to note that the IC50 values for inhibition of aromatase
activity by 8-PN and letrozole were in the same range.
Similarly, the strong inhibitory effects of 8-PN (IC50 value
of  100 nM)  on aromatase activity was previously demon-
strated by Duursen et al. in human adrenal H295R cells
[63].  Further studies will need to be performed to show the
nature  of the aromatase inhibitory actions of 8-PN. Inter-
estingly, our study demonstrated, that in contrast to 8-PN
(3  M),  NAR (3 M)  stimulated CYP19A1 activity but not
at  mRNA level. Also COU (10 M)  and RSV (10 M)  did
not affect CYP19A1 mRNA levels. COU has previously been
shown  to be a weak competitive inhibitor of aromatase
enzyme activity in human preadipocytes [24]. In addition,
the  previous studies showed that RSV (50 M)  inhibited
the transactivation of aromatase promoters I.3 and II in
SK-BR-3 cells and it inhibited (IC50 value of 25 M)  aro-
matase activity in MCF-7 cells [64]. Further research on
phytoestrogen QUE, NAR, COU-induced aromatase activ-
ity  is needed to conﬁrm a direct involvement of CREB1 on
CYP191A  modulation. The seemingly contradictory results
regarding modulation of aromatase activity upon expo-
sure  to phytoestrogens could be due the use of different
in vitro models. As extensively described above, human
aromatase is regulated in a highly tissue-speciﬁc man-
ner.  This implies that cells from different origins might
respond differently to phytoestrogens. Our studies were
performed using the human KGN cell line, which has previ-
ously  been shown to be an excellent and applicable in vitro
logy Rep368 K.A. Solak et al. / Toxico
model to study effects on human granulosa cell function-
ing.  Further studies should be performed to conﬁrm the
effects  on human granulosa cells and could include pri-
mary  human granulosa cells, however, be believe this is
beyond  the scope of our study. Also, different experimen-
tal set-up, i.e. medium types, solvent used and exposure
times, can contribute greatly to the observed effects. The
enzymes  of P450 family are highly stable proteins with
half-life of 24–42 h [65]. In contrast, the half-life of mRNA
has  been reported to range from 10 to 30 h depending on
tissue  investigated [66,67]. The lack of correlation between
mRNA  and protein levels of CYP19A1 after 24 h in our
study most likely reﬂect the different half-lives of mRNA
and  the aromatase protein. Moreover, study of Shozu et al.
provided  evidence of other non-genomic modes of post-
transcriptional regulation of aromatase via modulation of
mitogen-activated protein kinase (MAPK) pathways [68].
Bearing  in mind that phytoestrogens were shown to mod-
ulate  several kinase signaling pathways including MAPK
and/or  Akt/protein kinase B (PKB) [69,70], direct regu-
lation of aromatase activity by phytoestrogens without
detectable changes at mRNA or protein levels may  occur.
Further research is needed to elucidate the modulation of
aromatase  activity via these mechanisms by plant-derived
compounds. In the present study, we also demonstrated
that phytoestrogens can induce Steroidogenic acute regu-
latory  protein (StAR) mRNA levels in ganulosa KGN cells.
StAR  plays a crucial role in regulation of steroidogenesis
by transporting steroid from cytosol into the mitochon-
dria [16,17]. All tested phytoestrogens, except NAR and
GEN,  statistically signiﬁcantly increased StAR mRNA lev-
els  up to 2-fold. To date, only several studies reported
phytoestrogen-mediated effects on StAR gene and protein
expression in granulosa cells. Chen et al. reported that
RSV  and GEN inhibited mouse Star mRNA, whereas QUE
induced Star mRNA levels in murine MA-10 Leydig cells
[71].  8-PN has been shown to exert age-dependent effects
on  steroidogenesis by up-regulating mRNA levels of Star in
progenitor  and immature but not adult types of rat Leydig
cells  [72]. Similarly to our results, StAR mRNA levels were
signiﬁcantly up-regulated by 100 M RSV in rat granulosa
cells after 24 h [32].
Many phytoestrogens, including RSV, GEN and QUE,
have been shown to bind to both ER and/or ER and
induce the transcription of estrogen-responsive target
genes [73,12,74]. Yet, despite of the structural similar-
ity  with E2, relative binding afﬁnities of phytoestrogens
for the ER are at least 1000–10000 times lower com-
pared to E2 and generally show stronger binding afﬁnity
for  the ER [12]. An exception here is 8-PN. It is well-
known, that NAR possess a higher relative estrogenic
potency (REP) toward ER than ER [75,76]. Prenyla-
tion at the 8-position of NAR increases estrogenicity [75]
and  8-PN has been described to possess a higher rela-
tive  estrogenic potency (REP) in activation of ER (10−2)
than  ER (3.9 × 103) [76]. Because of the known interac-
tion of phytoestrogens with ERs and the observed effects on
aromatase,  we investigated whether phytoestrogens can
alter  aromatase expression via ER-mediated pathways. We
investigated whether the known antiestrogen ICI 182,780
possess modulatory effects upon aromatase. ICI 182,780orts 1 (2014) 360–372
has  been shown to disrupt the nucleocytoplasmic shutt-
ling  of ER that results in nuclear exclusion of the ER
and the increase of its turnover and protein degradation
[77]. The present study shows that exposure to ICI 182,780
resulted in a concentration-dependent inhibition of aro-
matase  activity in KGN cells. Our results are in agreement
with others, who also observed a concentration-dependent
decrease of aromatase activity after ICI 182,780 treatment
in  MCF-7 cells, human ﬁbroblasts and trophoblast cells
[78–80]. The inhibitory mechanism of ICI 182, 780 upon
aromatase remains unknown. However, it was demon-
strated that inhibition of aromatase activity by ICI 182,780
is  not via interaction with the ER, since the aromatase activ-
ity  was  also suppressed in ER-negative cells after exposure
to  ICI 182,780 [78]. This concurs with our ﬁndings that
E2  alone did not affect aromatase activity in KGN cells.
In  our study, co-exposure of KGN cells to ICI 182,780
(0.1 M)  together with COU (10 M),  QUE (10 M)  statis-
tically signiﬁcantly decreased aromatase activity by 46%
and  73%, respectively, when compared to COU and QUE
alone.  Interestingly, NAR (3 M)-mediated stimulation of
aromatase activity was  not attenuated by ICI 182,780 co-
treatment, suggesting that the effects of NAR on aromatase
is  not mediated by ER signaling pathways. It would be
toxicologically relevant to further explore the mechanism
behind the role of ERs in granulosa cells and modulation
of aromatase activity and gene expression by phytoestro-
gens. KGN cells have been shown to express ER, ER but
also  estrogen-related receptor GPER1 [81]. Recent research
has  highlighted the cross-talk of both genomic and non-
genomic activities of ERs. Here, we  have only performed
studies with a selective ER inhibitor, but future studies
could include the roles of ER and estrogen-related recep-
tor  GPER1 as well. However, this was beyond the scope of
our  study.
Inhibition of E2 biosynthesis by selective blockade of
the  aromatase enzyme has become an established method
of  hormonal treatment in estrogen-dependent malignant
conditions of ER-positive breast cancers. Granulosa cell
tumors  (GCT) are hormonally sensitive and characterize
with excretion of high levels of aromatase activity and fre-
quently  secrete estrogens [82]. Treatment of women with
GCT  has been positively correlated with the responses to
hormonal  manipulations with aromatase inhibitors [83].
The  interest in the potential beneﬁts of diets high in phy-
toestrogens has increased, especially with regard to cancer
chemoprevention. Yet, despite intense investigation, many
studies  give inconclusive answers whether phytoestro-
gens are suitable as cancer chemopreventive agents. In
this  study, we show that the tested phytoestrogens can
affect  migration of human KGN granulosa-like tumor cells
as  assessed by a wound healing assay. Similarly, another
study described that RSV (IC50 of 18.8 M)  and QUE (IC50
of 37.5 M)  inhibited the migration of vascular endothelial
cells in a concentration-dependent manner [84]. It is well
known  that neovascularization is a crucial factor in tumor
growth, invasion, and metastasis [85,86]. In line with this,
QUE  was  shown to decrease VEGF secretion by myeloblas-
tic leukemia cells NB4 [87] and possess inhibitory effects
on  proliferation, migration and tube formation of endothe-
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nhibit VEGF production and suppress ovarian cancer cell
etastasis in vitro [88]. Yet, in our study, only 10 M GEN
aused an up-regulation of VEGF mRNA expression. Data
rom  previous studies demonstrated that GEN can also
educe  expression of SIRT1. In the present study, SIRT1 gene
xpression was only signiﬁcantly up-regulated by 8-PN.
lso,  gene expression of CADHERIN E and MMP9  were not
ffected  in KGN cells exposed to tested phytoestrogens.
hese data show that the tested phytoestrogens reduced
GN  cell migration, which is in line with the proposed can-
er  preventive actions of phytoestrogens. However, found
o  molecular pathways that could explain the inhibition of
igration  of KGN cells in this study and cell cycle status and
roliferation were unaltered in our experimental set-up.
Upon  normal dietary intake of isoﬂavones, the pre-
ominant group of phytoestrogens in Western countries,
ypically reach blood levels that are in the nanomolar
ange [89]. However, with vegan and vegetarian diets that
re  rich in isoﬂavones, plasma isoﬂavone concentrations
re reported to easily reach micromolar concentrations,
epending on the phytoestrogen nature and the food
ource [90].
Several studies have described high peak plasma lev-
ls  of phytoestrogen in humans upon dietary intake of
hytoestrogens. For example, mean peak plasma levels of
UE  were 0.30 and 0.74 M after consumption of apples
325  M)  or onions (225 M of QUE), respectively [91].
imilarly, 6 h after ingestion of 60 g of baked soybean pow-
er  containing 112 mol  GEN, a mean peak plasma level
f  2.44 ± 0.65 mol  GEN/L was detected [92]. With regard
o  RSV, total plasma levels of RSV were found to reach
.33 ± 0.3 mol/L and 1.72 ± 0.1 mol/L after white and red
ine  intake, respectively [93]. Also, peak plasma concen-
rations of NAR of 6.0 ± 5.4 mol/L were found in humans
pon an ingestion of grapefruit juice (8 ml/kg body weight)
94].  Beside dietary intake, many phytoestrogens are also
eadily  available as dietary supplements that can contain
aily  dosages up to 1200 mg  of QUE, GEN or 8-PN for
xample [63,95], which are several orders of magnitude
igher than the dietary intake described above. It has been
emonstrated that the bioavailability of soy isoﬂavones
s higher after ingestion of soy-based supplements than
fter  soy-rich food [96]. Several studies described peak
lasma levels upon a high single oral dose of phytoestro-
ens. For example, a kinetic study with healthy women
howed 8-PN peak plasma concentrations up to 220 nM
fter  a single oral dose of 750 mg  8-PN [97]. Here, we
escribed that 8-PN inhibited aromatase activity with an
C50 value of 8 nM,  suggesting that our effect concentration
s 1–2 orders of magnitude lower than reported human
lasma levels for 8-PN. Still, a key obstacle in human
isk assessment of phytoestrogen-containing supplements
ies in the lack of human relevant pharmacokinetic data.
ndividual differences in gut microﬂora, (renal) clearance,
enetic polymorphisms in metabolizing enzymes, differ-
nces  in supplementation dose and type of phytoestrogen
ource all contribute to disparate plasma levels of phytoes-
rogens that have been reported in humans. Furthermore,
he lack of the correlation of plasma levels with tissue con-
entrations, e.g. in the ovary hampers proper human risk
ssessment of phytoestrogens. In the present study, theorts 1 (2014) 360–372 369
ﬁnal  concentrations of tested phytoestrogens were in the
micromolar range, which is in the same order of magnitude
as  generally reported plasma levels upon intake of these
phytoestrogens with dietary supplements. However, sup-
plements  are typically taken on a daily basis, which leads
to  prolonged high systemic exposure to these bioactive
compounds. The complexity of phytoestrogen actions is
increased  by the fact that these compounds are frequently
present as mixtures of several dietary components that
can  affect multiple signaling pathways or the same path-
ways  resulting in additive, synergistic or opposing effects.
Based  on the effect concentrations from our study and the
reported  human plasma levels, we conclude that it is not
unlikely that adverse effects on ovarian function can occur
after  intake of high doses of phytoestrogens via dietary sup-
plements.  Yet, for better human risk assessment of these
compounds, understanding the pharmacokinetics and the
combined  effects of phytoestrogens on steroidogenic pro-
cesses  is crucial and needs to be addressed further.
5. Conclusion
Our study shows that some phytoestrogens can mod-
ulate promoter II and I.3-driven aromatase in KGN
granulosa-like tumor cells, which could lead to altered
ovarian estrogen production. Most strikingly were the
effects  of 8-PN that displayed even a more potent inhibition
of  aromatase activity than the therapeutic compound letro-
zole,  while simultaneously it induced CYP19 mRNA levels.
We  also showed that most phytoestrogens reduced KGN
cell  migration. Our study indicates that the use of dietary
supplements with high contents of phytoestrogens may
interfere with normal female ovarian function and that
caution is in place when taking these supplements.
Conﬂict of interest
The  authors declare that there are no conﬂicts of
interest.
Transparency document
The  Transparency document associated with this article
can be found in the online version.
Acknowledgements
This work was  ﬁnancially supported by the
Doerenkamp-Zbinden Foundation.
References
[1] K.D. Setchell, Phytoestrogens: the biochemistry, physiology, and
implications for human health of soy isoﬂavones, Am.  J. Clin. Nutr.
68  (6 Suppl.) (1998) 1333S–1346S.
[2] D.C. Knight, J.A. Eden, A review of the clinical effects of phytoestro-
gens, Obstet. Gynecol. 87 (5 Pt 2) (1996) 897–904.
[3]  A. Cassidy, S. Milligan, How signiﬁcant are environmental estrogens
to  women? Climacteric 1 (3) (1998) 229–242.
[4]  T. Kouki, M.  Kishitake, M.  Okamoto, I. Oosuka, M.  Takebe, K.
Yamanouchi, Effects of neonatal treatment with phytoestrogens,
genistein and daidzein, on sex difference in female rat brain function:





































[370 K.A. Solak et al. / Toxico
[5] Y. Nikaido, K. Yoshizawa, N. Danbara, M.  Tsujita-Kyutoku, T. Yuri,
N.  Uehara, A. Tsubura, Effects of maternal xenoestrogen exposure on
development of the reproductive tract and mammary gland in female
CD-1  mouse offspring, Reprod. Toxicol. 18 (6) (2004) 803–811.
[6] K.B. Delclos, C.C. Weis, T.J. Bucci, G. Olson, P. Mellick, N. Sadovova, J.R.
Latendresse, B. Thorn, R.R. Newbold, Overlapping but distinct effects
of  genistein and ethinyl estradiol (EE(2)) in female Sprague-Dawley
rats in multigenerational reproductive and chronic toxicity studies,
Reprod. Toxicol. 27 (2) (2009) 117–132.
[7]  H.W. Bennetts, E.J. Underwood, F.L. Shier, A speciﬁc breeding prob-
lem  of sheep on subterranean clover pastures in Western Australia,
Aust. Vet. J. 22 (1946) 2–12.
[8] K. Kallela, K. Heinonen, H. Saloniemi, Plant oestrogens; the cause of
decreased  fertility in cows. A case report, Nord. Vet. Med. 36 (3–4)
(1984) 124–129.
[9] A. Amsterdam, N. Abu-Rustum, J. Carter, M.  Krychman, Persistent
sexual arousal syndrome associated with increased soy intake, J. Sex.
Med.  2 (3) (2005) 338–340.
10] A. Chandrareddy, O. Muneyyirci-Delale, S.I. McFarlane, O.M. Murad,
Adverse effects of phytoestrogens on reproductive health: a report
of  three cases, Complement. Ther. Clin. Pract. 14 (2) (2008) 132–135.
11] J. Kim, S. Kim, K. Huh, Y. Kim, H. Joung, M.  Park, High serum isoﬂavone
concentrations are associated with the risk of precocious puberty in
Korean  girls, Clin. Endocrinol. (Oxf.) 75 (6) (2011) 831–835.
12] G.G. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P.T. van der
Saag,  B. van der Burg, J.A. Gustafsson, Interaction of estrogenic chem-
icals  and phytoestrogens with estrogen receptor beta, Endocrinology
139 (10) (1998) 4252–4263.
13] S.C. Sharma, J.W. Clemens, M.D. Pisarska, J.S. Richards, Expression and
function  of estrogen receptor subtypes in granulosa cells: regulation
by  estradiol and forskolin, Endocrinology 140 (9) (1999) 4320–4334.
14] T. Lorand, E. Vigh, J. Garai, Hormonal action of plant derived
and anthropogenic non-steroidal estrogenic compounds: phyto-
estrogens and xenoestrogens, Curr. Med. Chem. 17 (30) (2010)
3542–3574.
15]  E.R. Prossnitz, M.  Barton, Signaling, physiological functions and clin-
ical  relevance of the G protein-coupled estrogen receptor GPER,
Prostaglandins Other Lipid Mediat. 89 (3–4) (2009) 89–97.
16] B.J. Clark, J. Wells, S.R. King, D.M. Stocco, The puriﬁcation, cloning, and
expression  of a novel luteinizing hormone-induced mitochondrial
protein in MA-10 mouse Leydig tumor cells. Characterization of the
steroidogenic acute regulatory protein (StAR), J. Biol. Chem. 269 (45)
(1994)  28314–28322.
17] B.J. Clark, D.M. Stocco, Steroidogenic acute regulatory protein: the
StAR  still shines brightly, Mol. Cell. Endocrinol. 134 (1) (1997) 1–8.
18] E.R. Simpson, Y. Zhao, V.R. Agarwal, M.D. Michael, S.E. Bulun, M.M.
Hinshelwood, S. Graham-Lorence, T. Sun, C.R. Fisher, K. Qin, C.R.
Mendelson, Aromatase expression in health and disease, Recent Prog.
Horm.  Res. 52 (1997) 185–213, discussion 213-4.
19]  E.R. Simpson, S.R. Davis, Minireview: aromatase and the regulation of
estrogen  biosynthesis – some new perspectives, Endocrinology 142
(11)  (2001) 4589–4594.
20] F. Naftolin, K.J. Ryan, Z. Petro, Aromatization of androstenedione by
the  anterior hypothalamus of adult male and female rats, Endocrinol-
ogy 90 (1) (1972) 295–298.
21] S.E. Bulun, S. Sebastian, K. Takayama, T. Suzuki, H. Sasano, M.  Shozu,
The  human CYP19 (aromatase P450) gene: update on physiologic
roles and genomic organization of promoters, J. Steroid Biochem.
Mol. Biol. 86 (3–5) (2003) 219–222.
22] E.R. Simpson, Aromatase: biologic relevance of tissue-speciﬁc
expression, Semin. Reprod. Med. 22 (1) (2004) 11–23.
23] S. Ohno, F. Yukinawa, M.  Noda, S. Nakajin, Mono-(2-ethylhexyl)
phthalate induces NR4A subfamily and GIOT-1 gene expression, and
suppresses CYP19 expression in human granulosa-like tumor cell
line  KGN, Toxicol. Lett. 191 (2–3) (2009) 353–359.
24]  C. Wang, T. Makela, T. Hase, H. Adlercreutz, M.S. Kurzer, Lignans
and ﬂavonoids inhibit aromatase enzyme in human preadipocytes,
J. Steroid Biochem. Mol. Biol. 50 (3–4) (1994) 205–212.
25] Y. Wang, W.  Man  Gho, F.L. Chan, S. Chen, L.K. Leung, The red clover
(Trifolium pratense) isoﬂavone biochanin A inhibits aromatase activ-
ity  and expression, Br. J. Nutr. 99 (2) (2008) 303–310.
26] D.R. Campbell, M.S. Kurzer, Flavonoid inhibition of aromatase
enzyme activity in human preadipocytes, J. Steroid Biochem. Mol.
Biol.  46 (3) (1993) 381–388.27] H. Adlercreutz, C. Bannwart, K. Wahala, T. Makela, G. Brunow, T. Hase,
P.J.  Arosemena, J.T. Kellis Jr., L.E. Vickery, Inhibition of human aro-
matase  by mammalian lignans and isoﬂavonoid phytoestrogens, J.
Steroid  Biochem. Mol. Biol. 44 (2) (1993) 147–153.
[orts 1 (2014) 360–372
28] S. Rice, H.D. Mason, S.A. Whitehead, Phytoestrogens and their low
dose  combinations inhibit mRNA expression and activity of aro-
matase in human granulosa-luteal cells, J. Steroid Biochem. Mol. Biol.
101  (4–5) (2006) 216–225.
29] J.A. van Meeuwen, S. Nijmeijer, T. Mutarapat, S. Ruchirawat, P.C. de
Jong,  A.H. Piersma, M.  van den Berg, Aromatase inhibition by syn-
thetic  lactones and ﬂavonoids in human placental microsomes and
breast  ﬁbroblasts – a comparative study, Toxicol. Appl. Pharmacol.
228 (3) (2008) 269–276.
30] M.B. van Duursen, S.M. Nijmeijer, E.S. de Morree, P.C. de Jong, M.  van
den  Berg, Genistein induces breast cancer-associated aromatase and
stimulates  estrogen-dependent tumor cell growth in in vitro breast
cancer model, Toxicology 289 (2–3) (2011) 67–73.
31]  J.T. Sanderson, J. Hordijk, M.S. Denison, M.F. Springsteel, M.H.  Nantz,
M.  van den Berg, Induction and inhibition of aromatase (CYP19) activ-
ity  by natural and synthetic ﬂavonoid compounds in H295R human
adrenocortical carcinoma cells, Toxicol. Sci. 82 (1) (2004) 70–79.
32] Y. Morita, O. Wada-Hiraike, T. Yano, A. Shirane, M.  Hirano, H. Hiraike,
S.  Koyama, H. Oishi, O. Yoshino, Y. Miyamoto, K. Sone, K. Oda, S.
Nakagawa, K. Tsutsui, Y. Taketani, Resveratrol promotes expression
of  SIRT1 and StAR in rat ovarian granulosa cells: an implicative
role of SIRT1 in the ovary, Reprod. Biol. Endocrinol. 10 (2012),
14-7827-10-14.
33] S.S. Chen, A. Michael, S.A. Butler-Manuel, Advances in the treatment
of  ovarian cancer: a potential role of antiinﬂammatory phytochemi-
cals, Discov. Med. 13 (68) (2012) 7–17.
34]  M.  Hedelin, M.  Lof, T.M. Andersson, H. Adlercreutz, E. Weiderpass,
Dietary phytoestrogens and the risk of ovarian cancer in the women’s
lifestyle and health cohort study, Cancer Epidemiol. Biomarkers Prev.
20  (2) (2011) 308–317.
35] Y. Nishi, T. Yanase, Y. Mu,  K. Oba, I. Ichino, M.  Saito, M.  Nomura,
C. Mukasa, T. Okabe, K. Goto, R. Takayanagi, Y. Kashimura, M.  Haji,
H.  Nawata, Establishment and characterization of a steroidogenic
human granulosa-like tumor cell line, KGN, that expresses functional
follicle-stimulating hormone receptor, Endocrinology 142 (1) (2001)
437–445.
36]  I. Deura, T. Harada, F. Taniguchi, T. Iwabe, M.  Izawa, N. Ter-
akawa, Reduction of estrogen production by interleukin-6 in
a  human granulosa tumor cell line may have implications for
endometriosis-associated infertility, Fertil. Steril. 83 (Suppl. 1)
(2005) 1086–1092.
37] K. Horling, A.N. Santos, B. Fischer, The AhR is constitutively activated
and  affects granulosa cell features in the human cell line KGN, Mol.
Hum.  Reprod. 17 (2) (2011) 104–114.
38] M.  Alexiadis, N. Eriksson, S. Jamieson, M.  Davis, A.E. Drummond, S.
Chu,  C.D. Clyne, G.E. Muscat, P.J. Fuller, Nuclear receptor proﬁling of
ovarian  granulosa cell tumors, Horm. Cancer 2 (3) (2011) 157–169.
39] M.  Reverchon, M. Cornuau, C. Rame, F. Guerif, D. Royere, J.
Dupont, Chemerin inhibits IGF-1-induced progesterone and estra-
diol  secretion in human granulosa cells, Hum. Reprod. 27 (6) (2012)
1790–1800.
40]  J. Kwintkiewicz, Y. Nishi, T. Yanase, L.C. Giudice, Peroxisome
proliferator-activated receptor-gamma mediates bisphenol A inhi-
bition  of FSH-stimulated IGF-1, aromatase, and estradiol in human
granulosa cells, Environ. Health Perspect. 118 (3) (2010) 400–406.
41] M.  Reverchon, M.  Cornuau, L. Cloix, C. Rame, F. Guerif, D. Royere,
J.  Dupont, Visfatin is expressed in human granulosa cells: regula-
tion  by metformin through AMPK/SIRT1 pathways and its role in
steroidogenesis, Mol. Hum. Reprod. 19 (5) (2013) 313–326.
42] S. Elangovan, S. Ramachandran, N. Venkatesan, S. Ananth, J.P.
Gnana-Prakasam, P.M. Martin, D.D. Browning, P.V. Schoenlein, P.D.
Prasad,  V. Ganapathy, M.  Thangaraju, SIRT1 is essential for onco-
genic signaling by estrogen/estrogen receptor alpha in breast cancer,
Cancer  Res. 71 (21) (2011) 6654–6664.
43] F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and
survival. Modiﬁcations to the tetrazolium dye procedure giving
improved sensitivity and reliability, J. Immunol. Methods 89 (2)
(1986)  271–277.
44] E. Attar, S.E. Bulun, Aromatase and other steroidogenic genes in
endometriosis: translational aspects, Hum. Reprod. Update 12 (1)
(2006)  49–56.
45] M.  Heneweer, M.  van den Berg, J.T. Sanderson, A comparison of
human  H295R and rat R2C cell lines as in vitro screening tools for
effects  on aromatase, Toxicol. Lett. 146 (2) (2004) 183–194.46] Y.H. Zhou, F. Tan, K.R. Hess, W.K. Yung, The expression of PAX6,
PTEN, vascular endothelial growth factor, and epidermal growth fac-
tor  receptor in gliomas: relationship to tumor grade and survival,











































[K.A. Solak et al. / Toxico
47] E.D. Lephart, E.R. Simpson, Assay of aromatase activity, Methods
Enzymol. 206 (1991) 477–483.
48] J.T. Sanderson, R.J. Letcher, M.  Heneweer, J.P. Giesy, M.  van den Berg,
Effects  of chloro-s-triazine herbicides and metabolites on aromatase
activity in various human cell lines and on vitellogenin production
in male carp hepatocytes, Environ. Health Perspect. 109 (10) (2001)
1027–1031.
49]  O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein measure-
ment  with the Folin phenol reagent, J. Biol. Chem. 193 (1) (1951)
265–275.
50]  C. Wang, X. Lv, C. Jiang, C.M. Cordes, L. Fu, S.M. Lele, J.S. Davis, Trans-
forming growth factor alpha (TGFalpha) regulates granulosa cell
tumor  (GCT) cell proliferation and migration through activation of
multiple  pathways, PLOS ONE 7 (11) (2012) e48299.
51] D. Jackson, P.R. Cook, Analyzing DNA replication I: labeling animals,
tissues, and cells with bromodeoxyuridine (BrdU), CSH Protoc. 2008
(2008),  http://dx.doi.org/10.1101/pdb.prot5031.
52] S. Sangjun, E. de Jong, S. Nijmeijer, T. Mutarapat, S. Ruchirawat, M.
van  den Berg, M.B. van Duursen, Induction of cell cycle arrest in
human  MCF-7 breast cancer cells by cis-stilbene derivatives related
to  VIOXX, Toxicol. Lett. 186 (2) (2009) 115–122.
53]  S.E. Bulun, K.M. Zeitoun, K. Takayama, H. Sasano, Estrogen biosynthe-
sis  in endometriosis: molecular basis and clinical relevance, J. Mol.
Endocrinol. 25 (1) (2000) 35–42.
54] S.E. Bulun, Z. Lin, G. Imir, S. Amin, M.  Demura, B. Yilmaz, R. Martin,
H.  Utsunomiya, S. Thung, B. Gurates, M. Tamura, D. Langoi, S. Deb,
Regulation of aromatase expression in estrogen-responsive breast
and  uterine disease: from bench to treatment, Pharmacol. Rev. 57
(3)  (2005) 359–383.
55] S.E. Bulun, D. Chen, M.  Lu, H. Zhao, Y. Cheng, M.  Demura, B. Yilmaz, R.
Martin,  H. Utsunomiya, S. Thung, E. Su, E. Marsh, A. Hakim, P. Yin, H.
Ishikawa,  S. Amin, G. Imir, B. Gurates, E. Attar, S. Reierstad, J. Innes, Z.
Lin,  Aromatase excess in cancers of breast, endometrium and ovary,
J.  Steroid Biochem. Mol. Biol. 106 (1–5) (2007) 81–96.
56] G.D. Means, M.W.  Kilgore, M.S. Mahendroo, C.R. Mendelson, E.R.
Simpson, Tissue-speciﬁc promoters regulate aromatase cytochrome
P450 gene expression in human ovary and fetal tissues, Mol.
Endocrinol. 5 (12) (1991) 2005–2013.
57] C. Jenkins, D. Michael, M.  Mahendroo, E. Simpson, Exon-speciﬁc
northern analysis and rapid ampliﬁcation of cDNA ends (RACE) reveal
that  the proximal promoter II (PII) is responsible for aromatase
cytochrome P450 (CYP19) expression in human ovary, Mol. Cell.
Endocrinol. 97 (1–2) (1993) R1–R6.
58] J.T. Kellis Jr., L.E. Vickery, Inhibition of human estrogen synthetase
(aromatase) by ﬂavones, Science 225 (4666) (1984) 1032–1034.
59] S.A. Whitehead, M.  Lacey, Phytoestrogens inhibit aromatase but
not  17beta-hydroxysteroid dehydrogenase (HSD) type 1 in human
granulosa-luteal cells: evidence for FSH induction of 17beta-HSD,
Hum. Reprod. 18 (3) (2003) 487–494.
60] K.M. Edmunds, A.C. Holloway, D.J. Crankshaw, S.K. Agarwal, W.G.
Foster, The effects of dietary phytoestrogens on aromatase activ-
ity  in human endometrial stromal cells, Reprod. Nutr. Dev. 6 (2005)
709–720.
61]  S. Myllymaki, T. Haavisto, M.  Vainio, J. Toppari, J. Paranko,
In vitro effects of diethylstilbestrol, genistein, 4-tert-butylphenol,
and 4-tert-octylphenol on steroidogenic activity of isolated imma-
ture  rat ovarian follicles, Toxicol. Appl. Pharmacol. 204 (1) (2005)
69–80.
62]  L. Ye, M.Y. Chan, L.K. Leung, The soy isoﬂavone genistein
induces estrogen synthesis in the extragonadal pathway, Mol. Cell.
Endocrionol. (2009) 73–80.
63] M.B. van Duursen, E.E. Smeets, J.C. Rijk, S.M. Nijmeijer, M.  van
den  Berg, Phytoestrogens in menopausal supplements induce
ER-dependent cell proliferation and overcome breast cancer treat-
ment  in an in vitro breast cancer model, Toxicol. Appl. Pharmacol.
269 (2) (2013) 132–140.
64] Y. Wang, K.W. Lee, F.L. Chan, S. Chen, L.K. Leung, The red wine
polyphenol resveratrol displays bilevel inhibition on aromatase in
breast  cancer cells, Toxicol. Sci. 92 (1) (2006) 71–77.
65] I. Hanukoglu, Steroidogenic enzymes: structure, function, and role in
regulation  of steroid hormone biosynthesis, J. Steroid Biochem. Mol.
Biol.  43 (8) (1992) 779–804.
66] C. Genissel, J. Levallet, S. Carreau, Regulation of cytochrome P450
aromatase gene expression in adult rat Leydig cells: comparison with
estradiol  production, J. Endocrinol. 168 (1) (2001) 95–105.
67] Y.M. Mu,  T. Yanase, Y. Nishi, R. Takayanagi, K. Goto, H. Nawata, Com-
bined  treatment with speciﬁc ligands for PPARgamma:RXR nuclear
receptor system markedly inhibits the expression of cytochrome
[orts 1 (2014) 360–372 371
P450arom  in human granulosa cancer cells, Mol. Cell. Endocrinol.
181 (1–2) (2001) 239–248.
68] M.  Shozu, H. Sumitani, K. Murakami, T. Segawa, H.J. Yang, M.  Inoue,
Regulation of aromatase activity in bone-derived cells: possible role
of  mitogen-activated protein kinase, J. Steroid Biochem. Mol. Biol. 79
(1–5)  (2001) 61–65.
69] Y. Sanchez, D. Amran, E. de Blas, P. Aller, Regulation of
genistein-induced differentiation in human acute myeloid
leukaemia cells (HL60, NB4) protein kinase modulation and reactive
oxygen species generation, Biochem. Pharmacol. 77 (3) (2009)
384–396.
70]  J.P. Spencer, C. Rice-Evans, R.J. Williams, Modulation of pro-survival
Akt/protein kinase B and ERK1/2 signaling cascades by quercetin and
its  in vivo metabolites underlie their action on neuronal viability, J.
Biol.  Chem. 278 (37) (2003) 34783–34793.
71] Y.C. Chen, M.L. Nagpal, D.M. Stocco, T. Lin, Effects of genistein, resver-
atrol,  and quercetin on steroidogenesis and proliferation of MA-10
mouse Leydig tumor cells, J. Endocrinol. 192 (3) (2007) 527–537.
72] G. Izzo, O. Soder, K. Svechnikov, The prenylﬂavonoid phytoestrogens
8-prenylnaringenin and isoxanthohumol differentially suppress
steroidogenesis in rat Leydig cells in ontogenesis, J. Appl. Toxicol.
31  (6) (2011) 589–594.
73] J.L. Bowers, V.V. Tyulmenkov, S.C. Jernigan, C.M. Klinge, Resveratrol
acts as a mixed agonist/antagonist for estrogen receptors alpha and
beta,  Endocrinology 141 (10) (2000) 3657–3667.
74]  M.  Maggiolini, D. Bonoﬁglio, S. Marsico, M.L. Panno, B. Cenni, D.
Picard,  S. Ando, Estrogen receptor alpha mediates the proliferative
but not the cytotoxic dose-dependent effects of two major phyto-
estrogens on human breast cancer cells, Mol. Pharmacol. 60 (2001)
595–602.
75]  G. Kretzschmar, O. Zierau, J. Wober, S. Tischer, P. Metz, G. Vollmer,
Prenylation has a compound speciﬁc effect on the estrogenicity of
naringenin and genistein, J. Steroid Biochem. Mol. Biol. 118 (1–2)
(2010) 1–6.
76] T.F. Bovee, R.J. Helsdingen, I.M. Rietjens, J. Keijer, R.L. Hoogenboom,
Rapid yeast estrogen bioassays stably expressing human estrogen
receptors alpha and beta, and green ﬂuorescent protein: a com-
parison of different compounds with both receptor types, J. Steroid
Biochem. Mol. Biol. 91 (3) (2004) 99–109.
77]  S. Dauvois, R. White, M.G. Parker, The antiestrogen ICI 182780 dis-
rupts  estrogen receptor nucleocytoplasmic shuttling, J. Cell. Sci. 106
(Pt  4) (1993) 1377–1388.
78] S. Chen, D. Zhou, C. Yang, T. Okubo, Y. Kinoshita, B. Yu, Y.C. Kao, T.
Itoh,  Modulation of aromatase expression in human breast tissue, J.
Steroid  Biochem. Mol. Biol. 79 (1–5) (2001) 35–40.
79]  B.J. Long, S.L. Tilghman, W.  Yue, A. Thiantanawat, D.N. Grigoryev, A.M.
Brodie,  The steroidal antiestrogen ICI 182,780 is an inhibitor of cel-
lular  aromatase activity, J. Steroid Biochem. Mol. Biol. 67 (4) (1998)
293–304.
80]  P. Kumar, A. Kamat, C.R. Mendelson, Estrogen receptor alpha (ERal-
pha)  mediates stimulatory effects of estrogen on aromatase (CYP19)
gene  expression in human placenta, Mol. Endocrinol. 23 (6) (2009)
784–793.
81]  C. Wang, X. Lv, C. Jiang, J.S. Davis, The putative G-protein coupled
estrogen receptor agonist G-1 suppresses proliferation of ovarian and
breast  cancer cells in a GPER-independent manner, Am. J. Transl. Res.
4  (4) (2012) 390–402.
82] S.T. Schumer, S.A. Cannistra, Granulosa cell tumor of the ovary, J. Clin.
Oncol.  21 (6) (2003) 1180–1189.
83] S.A. Freeman, S.C. Modesitt, Anastrozole therapy in recurrent ovarian
adult  granulosa cell tumors: a report of 2 cases, Gynecol. Oncol. 103
(2)  (2006) 755–758.
84] K. Igura, T. Ohta, Y. Kuroda, K. Kaji, Resveratrol and quercetin inhibit
angiogenesis in vitro, Cancer Lett. 171 (1) (2001) 11–16.
85] J. Folkman, K. Watson, D. Ingber, D. Hanahan, Induction of angiogen-
esis during the transition from hyperplasia to neoplasia, Nature 339
(6219)  (1989) 58–61.
86] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation,
Cell  144 (5) (2011) 646–674.
87] L. Zhong, F.Y. Chen, H.R. Wang, Y. Ten, C. Wang, R.R. Ouyang, Effects of
quercetin  on morphology and VEGF secretion of leukemia cells NB4
in  vitro, Zhonghua Zhong Liu Za Zhi 28 (1) (2006) 25–27.
88] H. Luo, B.H. Jiang, S.M. King, Y.C. Chen, Inhibition of cell growth and
VEGF  expression in ovarian cancer cells by ﬂavonoids, Nutr. Cancer
60  (6) (2008) 800–809.
89] M.S. Morton, G. Wilcox, M.L. Wahlqvist, K. Grifﬁths, Determination of
lignans  and isoﬂavonoids in human female plasma following dietary









[97] M.  Rad, M.  Humpel, O. Schaefer, R.C. Schoemaker, W.D. Schleuning,372 K.A. Solak et al. / Toxico
90] S.J. Bhathena, M.T. Velasquez, Beneﬁcial role of dietary phytoes-
trogens in obesity and diabetes, Am.  J. Clin. Nutr. 76 (6) (2002)
1191–1201.
91]  P.C. Hollman, J.M. van Trijp, M.N. Buysman, M.S. van der Gaag, M.J.
Mengelers, J.H. de Vries, M.B. Katan, Relative bioavailability of the
antioxidant ﬂavonoid quercetin from various foods in man, FEBS Lett.
418  (1–2) (1997) 152–156.
92] S. Watanabe, M.  Yamaguchi, T. Sobue, T. Takahashi, T. Miura, Y. Arai,
W.  Mazur, K. Wahala, H. Adlercreutz, Pharmacokinetics of soybean
isoﬂavones in plasma, urine and feces of men  after ingestion of 60 g
baked  soybean powder (kinako), J. Nutr. 128 (10) (1998) 1710–1715.
93]  P. Pignatelli, A. Ghiselli, B. Buchetti, R. Carnevale, F. Natella, G.
Germanò, F. Fimognari, S. Di Santo, L. Lenti, F. Violi, Polyphenols syn-
ergistically inhibit oxidative stress in subjects given red and white
wine,  Atherosclerosis 1 (2006) 77–83.
94]  I. Erlund, E. Meririnne, G. Alfthan, A. Aro, Plasma kinetics and urinary
excretion of the ﬂavanones naringenin and hesperetin in humansorts 1 (2014) 360–372
after ingestion of orange juice and grapefruit juice, J. Nutr. 131 (2)
(2001)  235–241.
95] S. Egert, S. Wolffram, A. Bosy-Westphal, C. Boesch-Saadatmandi,
A.E. Wagner, J. Frank, G. Rimbach, M.J. Mueller, Daily quercetin
supplementation dose-dependently increases plasma quercetin con-
centrations in healthy humans, J. Nutr. 138 (9) (2008) 1615–1621.
96] S. Vergne, C. Bennetau-Pelissero, V. Lamothe, P. Chantre, M. Potier,
J.  Asselineau, P. Perez, M.  Durand, N. Moore, P. Sauvant, Higher
bioavailability of isoﬂavones after a single ingestion of a soya-based
supplement than a soya-based food in young healthy males, Br. J.
Nutr.  99 (2) (2008) 333–344.A.F. Cohen, J. Burggraaf, Pharmacokinetics and systemic endocrine
effects of the phyto-oestrogen 8-prenylnaringenin after single oral
doses  to postmenopausal women, Br. J. Clin. Pharmacol. 62 (3) (2006)
288–296.
